The global cell & gene therapy manufacturing services market size is projected to reach USD 13.8 billion by 2026 from USD 7.7billion in 2021, at a CAGR of 12.4% during the forecast period. Growth in this market is primarily driven by the high incidence of cancer and other target diseases, increasing investments in pharmaceutical R&D, investments in advanced technologies by CDMOs, and increasing partnerships & agreements between pharmaceutical companies and CDMOs. However, the high operational costs associated with cell & gene therapy manufacturing are expected to restrain the growth of this market to a certain extent.
“The clinical manufacturing segment accounted for the highest growth rate in thecell & gene therapy manufacturing servicesmarket, byapplication, during the forecast period”
The cell & gene therapy manufacturing services market is segmented into clinical manufacturing and commercial manufacturing on the basis of application. The clinical manufacturing segment accounted for the highest growth rate in the cell & gene therapy manufacturing servicesmarket during the forecast period. This segment's high growth rate can be attributed to increasing government funding for cancer research and the increasing number of cell & gene therapy clinical trials.
“Pharmaceutical & biotechnology companies segment accounted for the highest CAGR”
Based on end users, the cell & gene therapy manufacturing servicesmarket is segmented into pharmaceutical & biotechnology companies, academic & research institutes, and other end users. During the forecast periodpharmaceutical & biotechnology companies accounted for the highest growth rate. The high growth rate in this segment can be attributed to the increasing number of pharmaceutical companies outsourcing their preclinical studies to CROs.
“Cell Therapy segment accounted for the highest CAGR”
Based on type, the cell & gene therapy manufacturing servicesmarket is segmented intocell therapy and gene therapy. The cell therapy segment accounted for the highest growth rate during the forecast period. Growth in this market is mainly driven by the increasing awareness about cell therapy, growing funding for new cell lines, increasing partnerships and acquisitions, and the development of advanced genomics methods for cell analysis.
“Infectious diseases segment accounted for the highest CAGR”
Based on indication, the cell & gene therapy manufacturing servicesmarket is segmented into oncology diseases, cardiovascular diseases, orthopedic diseases, ophthalmology diseases, infectious diseases, central nervous system disorders, and other indications. Theinfectious diseases segment accounted for the highest growth rate during the forecast period. The growth of this segment is attributed to the rising clinical trials for the development of cell therapies owing to the increasing prevalence of infectious diseases.
“Asia Pacific: The fastest-growing countryin thecell & gene therapy manufacturing servicesmarket”
TheCell & gene therapy manufacturing servicesmarket is segmented into North America, Europe, Asia Pacific, Latin America and the Middle East and Africa. Asia Pacific is projected to register the highest CAGR during the forecast period. Increasing pharmaceutical R&D spending, the growing trend of outsourcing drug discovery services, growing life sciences research, and increasing government initiatives for healthcare research are the factors driving the growth of the cell & gene therapy manufacturing servicesmarket in this region.
The primary interviews conducted for this report can be categorized as follows:
• By Respondent: Supply Side- 70%, and Demand Side -30%
• By Designation (Supply Side): Managers - 45%, CXOs and Directors - 30%, and Executives- 25%
• By Region: North America -40%, Europe -25%, Asia-Pacific -20%, Latin America -10%, and Middle East and Africa -5%
Lists of Companies Profiled in the Report:
• Thermo Fisher Scientific, Inc. (US)
• Merck KGaA (Germany)
• Charles River Laboratories (US)
• Lonza (Switzerland)
• Catalent, Inc. (US)
• WuXiAppTec (China)
• Takara Bio Inc. (Japan)
• NIKON CORPORATION (Japan)
• FUJIFILM Holdings Corporation (Japan)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• Oxford Biomedica plc (UK)
• Cell and Gene Therapy Catapult (UK)
• The Discovery Labs LLC (US)
• RoslinCT (Scotland)
• JRS PHARMA (Germany)
• FinVector (Finland)
• ABL, Inc. (US)
• Resilience (US)
• BioCentriq (US)
• Porton Biopharma Limited (England)
• Andelyn Biosciences (US)
• Commercializing Living Therapies (Canada)
• Vibalogics (US)
• AnemocyteSrl (Italy)
• ElevateBio (US)
Research Coverage:
This report provides a detailed picture of the cell & gene therapy manufacturing servicesmarket. It aims at estimating the size and future growth potential of the market across different segments, such as type, indication, application, end user, and region. The report also includes an in-depth competitive analysis ofthe key market players, along with their company profiles, recent developments, and key market strategies.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall cell & gene therapy manufacturing servicesmarket and its subsegments.It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.
"1 INTRODUCTION 45
1.1 OBJECTIVES OF THE STUDY 45
1.2 MARKET DEFINITION 45
1.2.1 INCLUSIONS & EXCLUSIONS 45
1.3 MARKET SCOPE 46
1.3.1 MARKETS COVERED 46
1.3.2 YEARS CONSIDERED IN THE REPORT 47
1.4 CURRENCY 47
1.5 LIMITATIONS 47
1.6 STAKEHOLDERS 48
2 RESEARCH METHODOLOGY 49
2.1 RESEARCH DATA 49
FIGURE 1 RESEARCH DESIGN 49
2.1.1 SECONDARY DATA 50
2.1.2 PRIMARY DATA 50
FIGURE 2 PRIMARY SOURCES 51
FIGURE 3 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET:
BREAKDOWN OF PRIMARIES 51
2.1.2.1 Key industry insights 52
2.2 MARKET SIZE ESTIMATION 53
FIGURE 4 MARKET SIZE ESTIMATION: APPROACH 1 –
REVENUE SHARE ANALYSIS, 2020 53
FIGURE 5 AVERAGE MARKET SIZE ESTIMATION, 2020 54
FIGURE 6 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET:
CAGR PROJECTIONS, 2021–2026 55
FIGURE 7 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET:
GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, AND OPPORTUNITIES 56
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 57
FIGURE 8 DATA TRIANGULATION METHODOLOGY 57
2.4 RESEARCH ASSUMPTIONS 58
2.5 RISK ANALYSIS 58
3 EXECUTIVE SUMMARY 59
FIGURE 9 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE,
2021 VS. 2026 (USD MILLION) 59
FIGURE 10 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET,
BY INDICATION, 2021 VS. 2026 (USD MILLION) 60
FIGURE 11 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET,
BY APPLICATION, 2021 VS. 2026 (USD MILLION) 60
FIGURE 12 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY END USER, 2021 VS. 2026 (USD MILLION) 61
FIGURE 13 GEOGRAPHICAL SNAPSHOT OF THE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET 62
4 PREMIUM INSIGHTS 63
4.1 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET OVERVIEW 63
FIGURE 14 HIGH INCIDENCE OF CANCER AND OTHER TARGET DISEASES TO
DRIVE MARKET GROWTH 63
4.2 NORTH AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET,
BY TYPE & COUNTRY (2020) 64
FIGURE 15 THE CELL THERAPY SEGMENT ACCOUNTED FOR THE LARGEST SHARE OF
THE NORTH AMERICAN MARKET IN 2020 64
4.3 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SHARE,
BY APPLICATION, 2020 64
FIGURE 16 THE CLINICAL MANUFACTURING SEGMENT DOMINATED THE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET IN 2020 64
4.4 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY REGION, 2021–2026 65
FIGURE 17 ASIA PACIFIC TO REGISTER THE HIGHEST GROWTH RATE DURING THE FORECAST PERIOD 65
5 MARKET OVERVIEW 66
5.1 INTRODUCTION 66
5.2 MARKET DYNAMICS 66
FIGURE 18 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET:
DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 66
TABLE 1 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET:
IMPACT ANALYSIS 67
5.2.1 DRIVERS 67
5.2.1.1 High incidence of cancer and other target diseases 67
5.2.1.2 Increasing investments in pharmaceutical R&D 68
FIGURE 19 INCREASE IN GLOBAL PHARMACEUTICAL R&D SPENDING, 2012–2016 68
5.2.1.3 Investments in advanced technologies by CDMOs 69
5.2.1.4 Increasing partnerships and agreements between pharmaceutical companies and CDMOs 69
5.2.2 RESTRAINTS 70
5.2.2.1 High operational costs associated with cell & gene therapy manufacturing 70
5.2.3 OPPORTUNITIES 70
5.2.3.1 Rising demand for cell & gene therapies 70
5.2.3.2 Increasing number of cell & gene therapy clinical trials 71
5.2.4 CHALLENGES 71
5.2.4.1 Risk of mutagenesis and other unwanted outcomes 71
5.2.5 TRENDS 71
5.2.5.1 Expansion in emerging countries 71
5.3 IMPACT OF THE COVID-19 OUTBREAK ON THE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET 72
FIGURE 20 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SCENARIO, PRE-COVID-19 VS. POST-COVID-19 IMPACT, 2019–2021 73
5.4 TECHNOLOGICAL ANALYSIS 73
5.5 CASE STUDIES 74
5.5.1 CGT CATAPULT PROVIDED ITS EXPERTISE IN THERAPIES DEVELOPMENT
AND MANUFACTURING TO CREATE A NEW PRECLINICAL DEVELOPMENT PLAN FOR PURESPRING THERAPEUTICS’ GENE THERAPY TECHNOLOGY FOR
KIDNEY DISEASES 74
5.6 RANGES/SCENARIO 74
FIGURE 21 SPECTRUM OF SCENARIOS BASED ON THE IMPACT OF UNCERTAINTIES
ON THE GROWTH OF THE CELL & GENE THERAPY MANUFACTURING
SERVICES MARKET 74
5.7 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 75
FIGURE 22 REVENUE SHIFT & NEW POCKETS FOR CELL & GENE THERAPY MANUFACTURING SERVICE PROVIDERS 75
5.8 PRICING ANALYSIS 75
5.9 VALUE CHAIN ANALYSIS 75
FIGURE 23 VALUE CHAIN ANALYSIS OF THE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET: HARVESTING AND CRYOPRESERVATION PHASES ADD MAXIMUM VALUE 76
5.10 ECOSYSTEM ANALYSIS OF THE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET 76
FIGURE 24 ECOSYSTEM ANALYSIS OF THE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET 76
TABLE 2 SUPPLY CHAIN ECOSYSTEM 77
5.11 PORTER’S FIVE FORCES ANALYSIS 78
TABLE 3 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET:
PORTER’S FIVE FORCES ANALYSIS 78
5.11.1 THREAT FROM NEW ENTRANTS 78
5.11.2 THREAT FROM SUBSTITUTES 78
5.11.3 BARGAINING POWER OF BUYERS 78
5.11.4 BARGAINING POWER OF SUPPLIERS 78
5.11.5 INTENSITY OF COMPETITIVE RIVALRY 79
5.12 REGULATORY ANALYSIS 79
5.12.1 NORTH AMERICA 79
5.12.1.1 US 79
5.12.1.2 Canada 79
5.12.2 EUROPE 79
5.12.2.1 Germany 79
5.12.2.2 France 79
5.12.2.3 UK 80
5.12.2.4 Rest of Europe 80
5.12.3 ASIA PACIFIC 80
5.12.3.1 China 80
5.12.3.2 Japan 80
5.12.3.3 Rest of Asia Pacific 81
5.12.3.3.1 India 81
5.12.3.3.2 Australia and New Zealand 81
5.12.4 LATIN AMERICA 81
5.12.5 MIDDLE EAST & AFRICA 82
5.13 PATENT ANALYSIS 82
FIGURE 25 NUMBER OF PATENT APPLICATIONS FILED FOR CELL & GENE THERAPY MANUFACTURING SERVICES, JANUARY 2010–DECEMBER 2020 82
6 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE 83
6.1 INTRODUCTION 84
TABLE 4 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 84
6.2 CELL THERAPY 84
TABLE 5 CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 84
TABLE 6 CELL THERAPY MANUFACTURING SERVICES MARKET, BY REGION,
2019–2026 (USD MILLION) 85
TABLE 7 NORTH AMERICA: CELL THERAPY MANUFACTURING SERVICES MARKET,
BY COUNTRY, 2019–2026 (USD MILLION) 85
TABLE 8 EUROPE: CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 85
TABLE 9 ASIA PACIFIC: CELL THERAPY MANUFACTURING SERVICES MARKET,
BY COUNTRY, 2019–2026 (USD MILLION) 86
6.2.1 ALLOGENEIC 86
TABLE 10 ALLOGENEIC CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 86
TABLE 11 ALLOGENEIC CELL THERAPY MANUFACTURING SERVICES MARKET,
BY REGION, 2019–2026 (USD MILLION) 87
TABLE 12 NORTH AMERICA: ALLOGENEIC CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 87
TABLE 13 EUROPE: ALLOGENEIC CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 87
TABLE 14 ASIA PACIFIC: ALLOGENEIC CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 88
6.2.1.1 Mesenchymal stem cells 88
6.2.1.1.1 MSCs are ideal for cell therapy because of their immunosuppressive and tissue repair properties 88
TABLE 15 ALLOGENEIC MESENCHYMAL STEM CELL MANUFACTURING SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION) 88
TABLE 16 NORTH AMERICA: ALLOGENEIC MESENCHYMAL STEM CELL MANUFACTURING SERVICES MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 89
TABLE 17 EUROPE: ALLOGENEIC MESENCHYMAL STEM CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 89
TABLE 18 ASIA PACIFIC: ALLOGENEIC MESENCHYMAL STEM CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 89
6.2.1.2 T-cells 90
6.2.1.2.1 Allogeneic T-Cells are immediately available because of cryopreserved batches 90
TABLE 19 ALLOGENEIC T-CELL MANUFACTURING SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION) 90
TABLE 20 NORTH AMERICA: ALLOGENEIC T-CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 90
TABLE 21 EUROPE: ALLOGENEIC T-CELLS MANUFACTURING SERVICES MARKET,
BY COUNTRY, 2019–2026 (USD MILLION) 91
TABLE 22 ASIA PACIFIC: ALLOGENEIC T-CELL MANUFACTURING SERVICES MARKET,
BY COUNTRY, 2019–2026 (USD MILLION) 91
6.2.1.3 Induced pluripotent stem cells 91
6.2.1.3.1 Growing adoption Of IPSCs in research to
drive market growth 91
TABLE 23 ALLOGENEIC INDUCED PLURIPOTENT STEM CELL MANUFACTURING SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION) 92
TABLE 24 NORTH AMERICA: ALLOGENEIC INDUCED PLURIPOTENT STEM CELL MANUFACTURING SERVICES MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 92
TABLE 25 EUROPE: ALLOGENEIC INDUCED PLURIPOTENT STEM CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 92
TABLE 26 ASIA PACIFIC: ALLOGENEIC INDUCED PLURIPOTENT STEM CELL MANUFACTURING SERVICES MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 93
6.2.1.4 Natural killer cells 93
6.2.1.4.1 Allogeneic natural killer cell therapies are used for advanced hepatocellular carcinoma patients 93
TABLE 27 ALLOGENEIC NATURAL KILLER CELL MANUFACTURING SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION) 93
TABLE 28 NORTH AMERICA: ALLOGENEIC NATURAL KILLER CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 94
TABLE 29 EUROPE: ALLOGENEIC NATURAL KILLER CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 94
TABLE 30 ASIA PACIFIC: ALLOGENEIC NATURAL KILLER CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 94
6.2.1.5 Hematopoietic stem cells 95
6.2.1.5.1 Stem cells from a donor are used for allogeneic transplantation 95
TABLE 31 ALLOGENEIC HEMATOPOIETIC STEM CELL MANUFACTURING SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION) 95
TABLE 32 NORTH AMERICA: ALLOGENEIC HEMATOPOIETIC STEM CELL MANUFACTURING SERVICES MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 95
TABLE 33 EUROPE: ALLOGENEIC HEMATOPOIETIC STEM CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 96
TABLE 34 ASIA PACIFIC: ALLOGENEIC HEMATOPOIETIC STEM CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 96
6.2.1.6 Other allogeneic cells 96
TABLE 35 OTHER ALLOGENEIC CELL MANUFACTURING SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION) 97
TABLE 36 NORTH AMERICA: OTHER ALLOGENEIC CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 97
TABLE 37 EUROPE: OTHER ALLOGENEIC CELL MANUFACTURING SERVICES MARKET,
BY COUNTRY, 2019–2026 (USD MILLION) 97
TABLE 38 ASIA PACIFIC: OTHER ALLOGENEIC CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 98
6.2.2 AUTOLOGOUS 98
TABLE 39 AUTOLOGOUS CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 98
TABLE 40 AUTOLOGOUS CELL THERAPY MANUFACTURING SERVICES MARKET,
BY REGION, 2019–2026 (USD MILLION) 99
TABLE 41 NORTH AMERICA: AUTOLOGOUS CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 99
TABLE 42 EUROPE: AUTOLOGOUS CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 99
TABLE 43 ASIA PACIFIC: AUTOLOGOUS CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 100
6.2.2.1 T-cells 100
6.2.2.1.1 T-cells are major components of the adaptive
immune system 100
TABLE 44 AUTOLOGOUS T-CELL MANUFACTURING SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION) 101
TABLE 45 NORTH AMERICA: AUTOLOGOUS T-CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 101
TABLE 46 EUROPE: AUTOLOGOUS T-CELL MANUFACTURING SERVICES MARKET,
BY COUNTRY, 2019–2026 (USD MILLION) 101
TABLE 47 ASIA PACIFIC: AUTOLOGOUS T-CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 102
6.2.2.2 Hematopoietic stem cells 102
6.2.2.2.1 Hematopoietic stem cells are used to establish marrow
and bone function 102
TABLE 48 AUTOLOGOUS HEMATOPOIETIC STEM CELL MANUFACTURING SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION) 102
TABLE 49 NORTH AMERICA: AUTOLOGOUS HEMATOPOIETIC STEM CELL MANUFACTURING SERVICES MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 103
TABLE 50 EUROPE: AUTOLOGOUS HEMATOPOIETIC STEM CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 103
TABLE 51 ASIA PACIFIC: AUTOLOGOUS HEMATOPOIETIC STEM CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 103
6.2.2.3 Mesenchymal stem cells 104
6.2.2.3.1 Mesenchymal stem cells are present in the umbilical
cord, bone marrow, & fat tissue 104
TABLE 52 AUTOLOGOUS MESENCHYMAL STEM CELL MANUFACTURING SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION) 104
TABLE 53 NORTH AMERICA: AUTOLOGOUS MESENCHYMAL STEM CELL MANUFACTURING SERVICES MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 104
TABLE 54 EUROPE: AUTOLOGOUS MESENCHYMAL STEM CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 105
TABLE 55 ASIA PACIFIC: AUTOLOGOUS MESENCHYMAL STEM CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 105
6.2.2.4 Natural killer cells 105
6.2.2.4.1 NK Cells are used in the treatment of tumors and
infectious diseases 105
TABLE 56 AUTOLOGOUS NATURAL KILLER CELL MANUFACTURING SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION) 106
TABLE 57 NORTH AMERICA: AUTOLOGOUS NATURAL KILLER CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 106
TABLE 58 EUROPE: AUTOLOGOUS NATURAL KILLER CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 106
TABLE 59 ASIA PACIFIC: AUTOLOGOUS NATURAL KILLER CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 107
6.2.2.5 Other autologous cells 107
TABLE 60 OTHER AUTOLOGOUS CELL MANUFACTURING SERVICES MARKET,
BY REGION, 2019–2026 (USD MILLION) 107
TABLE 61 NORTH AMERICA: OTHER AUTOLOGOUS CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 108
TABLE 62 EUROPE: OTHER AUTOLOGOUS CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 108
TABLE 63 ASIA PACIFIC: OTHER AUTOLOGOUS CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 108
6.2.3 VIRAL VECTOR 109
TABLE 64 VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 109
TABLE 65 VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET,
BY REGION, 2019–2026 (USD MILLION) 109
TABLE 66 NORTH AMERICA: VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 110
TABLE 67 EUROPE: VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 110
TABLE 68 ASIA PACIFIC: VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 110
6.2.3.1 Retroviral vectors 111
6.2.3.1.1 Retroviral vectors are the most used viral vectors for cell therapy manufacturing 111
TABLE 69 RETROVIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION) 111
TABLE 70 NORTH AMERICA: RETROVIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 111
TABLE 71 EUROPE: RETROVIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 112
TABLE 72 ASIA PACIFIC: RETROVIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 112
6.2.3.2 Adeno-associated virus vectors 112
6.2.3.2.1 AAV vector-based techniques are used for car-t cell
therapy development 112
TABLE 73 ADENO-ASSOCIATED VIRUS VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION) 113
TABLE 74 NORTH AMERICA: ADENO-ASSOCIATED VIRUS VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 113
TABLE 75 EUROPE: ADENO-ASSOCIATED VIRUS VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 113
TABLE 76 ASIA PACIFIC: ADENO-ASSOCIATED VIRUS VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 114
6.2.3.3 Other viral vectors 114
TABLE 77 OTHER VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION) 114
TABLE 78 NORTH AMERICA: OTHER VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 115
TABLE 79 EUROPE: OTHER VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 115
TABLE 80 ASIA PACIFIC: OTHER VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 115
6.3 GENE THERAPY 116
TABLE 81 GENE THERAPY MANUFACTURING SERVICES MARKET, BY VECTOR,
2019–2026 (USD MILLION) 116
TABLE 82 GENE THERAPY MANUFACTURING SERVICES MARKET, BY REGION,
2019–2026 (USD MILLION) 116
TABLE 83 NORTH AMERICA: GENE THERAPY MANUFACTURING SERVICES MARKET,
BY COUNTRY, 2019–2026 (USD MILLION) 117
TABLE 84 EUROPE: GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 117
TABLE 85 ASIA PACIFIC: GENE THERAPY MANUFACTURING SERVICES MARKET,
BY COUNTRY, 2019–2026 (USD MILLION) 117
6.3.1 NON-VIRAL VECTORS 118
TABLE 86 NON-VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET,
BY TYPE, 2019–2026 (USD MILLION) 118
TABLE 87 NON-VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET,
BY REGION, 2019–2026 (USD MILLION) 118
TABLE 88 NORTH AMERICA: NON-VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 119
TABLE 89 EUROPE: NON-VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 119
TABLE 90 ASIA PACIFIC: NON-VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 119
6.3.1.1 Oligonucleotides 120
6.3.1.1.1 North America accounted for the largest share of the oligonucleotides market 120
TABLE 91 OLIGONUCLEOTIDE MANUFACTURING SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION) 120
TABLE 92 NORTH AMERICA: OLIGONUCLEOTIDE MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 120
TABLE 93 EUROPE: OLIGONUCLEOTIDE MANUFACTURING SERVICES MARKET,
BY COUNTRY, 2019–2026 (USD MILLION) 121
TABLE 94 ASIA PACIFIC: OLIGONUCLEOTIDE MANUFACTURING SERVICES MARKET,
BY COUNTRY, 2019–2026 (USD MILLION) 121
6.3.1.2 Other non-viral vectors 121
TABLE 95 OTHER NON-VIRAL VECTOR MANUFACTURING SERVICES MARKET,
BY REGION, 2019–2026 (USD MILLION) 122
TABLE 96 NORTH AMERICA: OTHER NON-VIRAL VECTOR MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 122
TABLE 97 EUROPE: OTHER NON-VIRAL VECTOR MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 122
TABLE 98 ASIA PACIFIC: OTHER NON-VIRAL VECTOR MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 123
6.3.2 VIRAL VECTORS 123
TABLE 99 VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET,
BY TYPE, 2019–2026 (USD MILLION) 123
TABLE 100 VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET,
BY REGION, 2019–2026 (USD MILLION) 124
TABLE 101 NORTH AMERICA: VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 124
TABLE 102 EUROPE: VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 124
TABLE 103 ASIA PACIFIC: VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 125
6.3.2.1 Retroviral vectors 125
6.3.2.1.1 Retroviral vectors possess the ability to replicate
within a cell 125
TABLE 104 RETROVIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION) 126
TABLE 105 NORTH AMERICA: RETROVIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 126
TABLE 106 EUROPE: RETROVIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 126
TABLE 107 ASIA PACIFIC: RETROVIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 127
6.3.2.2 Adeno-associated virus vectors 127
6.3.2.2.1 Adeno-associated virus vectors have low toxicity 127
TABLE 108 ADENO-ASSOCIATED VIRUS VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION) 128
TABLE 109 NORTH AMERICA: ADENO-ASSOCIATED VIRUS VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 128
TABLE 110 EUROPE: ADENO-ASSOCIATED VIRUS VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 128
TABLE 111 ASIA PACIFIC: ADENO-ASSOCIATED VIRUS VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 129
6.3.2.3 Other viral vectors 129
TABLE 112 OTHER VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION) 129
TABLE 113 NORTH AMERICA: OTHER VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 130
TABLE 114 EUROPE: OTHER VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 130
TABLE 115 ASIA PACIFIC: OTHER VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 130
7 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY INDICATION 131
7.1 INTRODUCTION 132
TABLE 116 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET,
BY INDICATION, 2019–2026 (USD MILLION) 132
7.2 ONCOLOGY DISEASES 132
7.2.1 THE DEMAND FOR CELL & GENE THERAPIES IS INCREASING WITH THE RISING NUMBER OF CANCER CASES WORLDWIDE 132
TABLE 117 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR ONCOLOGY DISEASES, BY REGION, 2019–2026 (USD MILLION) 133
TABLE 118 NORTH AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR ONCOLOGY DISEASES, BY COUNTRY,
2019–2026 (USD MILLION) 133
TABLE 119 EUROPE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR ONCOLOGY DISEASES, BY COUNTRY, 2019–2026 (USD MILLION) 134
TABLE 120 ASIA PACIFIC: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR ONCOLOGY DISEASES, BY COUNTRY, 2019–2026 (USD MILLION) 134
7.3 CARDIOVASCULAR DISEASES 134
7.3.1 GROWING INCIDENCE OF CARDIOVASCULAR DISEASES OWING TO SEDENTARY LIFESTYLES DRIVES THE MARKET GROWTH 134
TABLE 121 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2019–2026 (USD MILLION) 135
TABLE 122 NORTH AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY,
2019–2026 (USD MILLION) 135
TABLE 123 EUROPE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2019–2026 (USD MILLION) 135
TABLE 124 ASIA PACIFIC: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY,
2019–2026 (USD MILLION) 136
7.4 ORTHOPEDIC DISEASES 136
7.4.1 CELL THERAPY FOR ORTHOPEDIC DISEASES ELIMINATES
POST-TREATMENT COMPLICATIONS 136
TABLE 125 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR ORTHOPEDIC DISEASES, BY REGION, 2019–2026 (USD MILLION) 136
TABLE 126 NORTH AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR ORTHOPEDIC DISEASES, BY COUNTRY,
2019–2026 (USD MILLION) 137
TABLE 127 EUROPE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR ORTHOPEDIC DISEASES, BY COUNTRY, 2019–2026 (USD MILLION) 137
TABLE 128 ASIA PACIFIC: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR ORTHOPEDIC DISEASES, BY COUNTRY, 2019–2026 (USD MILLION) 137
7.5 OPTHALMOLOGY DISEASES 138
7.5.1 STEM CELL THERAPIES CAN BE USED FOR THE RESTORATION & PRESERVATION OF VISION; KEY FACTOR DRIVING MARKET GROWTH 138
TABLE 129 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR OPTHALMOLOGY DISEASES, BY REGION, 2019–2026 (USD MILLION) 138
TABLE 130 NORTH AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR OPTHALMOLOGY DISEASES, BY COUNTRY,
2019–2026 (USD MILLION) 138
TABLE 131 EUROPE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR OPTHALMOLOGY DISEASES, BY COUNTRY, 2019–2026 (USD MILLION) 139
TABLE 132 ASIA PACIFIC: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR OPTHALMOLOGY DISEASES, BY COUNTRY, 2019–2026 (USD MILLION) 139
7.6 CENTRAL NERVOUS SYSTEM DISORDERS 139
7.6.1 INCREASING INCIDENCE OF SPINAL MUSCULAR ATROPHY SUPPORTS
THE MARKET GROWTH 139
TABLE 133 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR CENTRAL NERVOUS SYSTEM DISORDERS, BY REGION, 2019–2026 (USD MILLION) 140
TABLE 134 NORTH AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR CENTRAL NERVOUS SYSTEM DISORDERS, BY COUNTRY,
2019–2026 (USD MILLION) 140
TABLE 135 EUROPE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR CENTRAL NERVOUS SYSTEM DISORDERS, BY COUNTRY,
2019–2026 (USD MILLION) 140
TABLE 136 ASIA PACIFIC: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR CENTRAL NERVOUS SYSTEM DISORDERS, BY COUNTRY,
2019–2026 (USD MILLION) 141
7.7 INFECTIOUS DISEASES 141
7.7.1 THE INCREASING PREVALENCE OF INFECTIOUS DISEASES TO DRIVE
THE MARKET GROWTH OF THIS SEGMENT 141
TABLE 137 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR INFECTIOUS DISEASES, BY REGION, 2019–2026 (USD MILLION) 142
TABLE 138 NORTH AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY,
2019–2026 (USD MILLION) 142
TABLE 139 EUROPE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2019–2026 (USD MILLION) 142
TABLE 140 ASIA PACIFIC: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2019–2026 (USD MILLION) 143
7.8 OTHER INDICATIONS 143
TABLE 141 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR OTHER INDICATIONS, BY REGION, 2019–2026 (USD MILLION) 143
TABLE 142 NORTH AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2019–2026 (USD MILLION) 144
TABLE 143 EUROPE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2019–2026 (USD MILLION) 144
TABLE 144 ASIA PACIFIC: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2019–2026 (USD MILLION) 144
8 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET,
BY APPLICATION 145
8.1 INTRODUCTION 146
TABLE 145 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET,
BY APPLICATION, 2019–2026 (USD MILLION) 146
8.2 CLINICAL MANUFACTURING 146
8.2.1 THE RISING NUMBER OF CLINICAL TRIALS FOR CELL & GENE THERAPIES IS EXPECTED TO DRIVE THE GROWTH OF THIS SEGMENT 146
TABLE 146 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR CLINICAL MANUFACTURING, BY REGION, 2019–2026 (USD MILLION) 147
TABLE 147 NORTH AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR CLINICAL MANUFACTURING, BY COUNTRY,
2019–2026 (USD MILLION) 147
TABLE 148 EUROPE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR CLINICAL MANUFACTURING, BY COUNTRY, 2019–2026 (USD MILLION) 147
TABLE 149 ASIA PACIFIC: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR CLINICAL MANUFACTURING, BY COUNTRY, 2019–2026 (USD MILLION) 148
8.3 COMMERCIAL MANUFACTURING 148
8.3.1 MARKET GROWTH CAN BE ATTRIBUTED TO THE INCREASING APPROVALS OF CELL & GENE THERAPY PRODUCTS FOR COMMERCIAL MANUFACTURING 148
TABLE 150 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR COMMERCIAL MANUFACTURING, BY REGION, 2019–2026 (USD MILLION) 148
TABLE 151 NORTH AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR COMMERCIAL MANUFACTURING, BY COUNTRY,
2019–2026 (USD MILLION) 149
TABLE 152 EUROPE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR COMMERCIAL MANUFACTURING, BY COUNTRY, 2019–2026 (USD MILLION) 149
TABLE 153 ASIA PACIFIC: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR COMMERCIAL MANUFACTURING, BY COUNTRY,
2019–2026 (USD MILLION) 149
9 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY END USER 150
9.1 INTRODUCTION 151
TABLE 154 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY END USER, 2019–2026 (USD MILLION) 151
9.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 151
9.2.1 GROWING NUMBER OF CELL & GENE THERAPIES IN THE R&D PIPELINE TO DRIVE THE MARKET GROWTH 151
TABLE 155 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION,
2019–2026 (USD MILLION) 152
TABLE 156 NORTH AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES,
BY COUNTRY, 2019–2026 (USD MILLION) 152
TABLE 157 EUROPE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY,
2019–2026 (USD MILLION) 153
TABLE 158 ASIA PACIFIC: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2019–2026 (USD MILLION) 153
9.3 ACADEMIC & RESEARCH INSTITUTES 153
9.3.1 INCREASE IN LIFE SCIENCES R&D EXPENDITURE TO CONTRIBUTE TO THE GROWTH OF THIS SEGMENT 153
TABLE 159 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2019–2026 (USD MILLION) 154
TABLE 160 NORTH AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY,
2019–2026 (USD MILLION) 154
TABLE 161 EUROPE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY,
2019–2026 (USD MILLION) 155
TABLE 162 ASIA PACIFIC: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY,
2019–2026 (USD MILLION) 155
9.4 OTHER END USERS 155
TABLE 163 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR OTHER END USERS, BY REGION, 2019–2026 (USD MILLION) 156
TABLE 164 NORTH AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2019–2026 (USD MILLION) 156
TABLE 165 EUROPE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2019–2026 (USD MILLION) 156
TABLE 166 ASIA PACIFIC: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2019–2026 (USD MILLION) 157
10 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY REGION 158
10.1 INTRODUCTION 159
TABLE 167 CELL & GENE THERAPY MANUFACTURING THERAPY SERVICES MARKET,
BY REGION, 2019–2026 (USD MILLION) 159
10.2 NORTH AMERICA 159
FIGURE 26 NORTH AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SNAPSHOT 160
TABLE 168 NORTH AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 160
TABLE 169 NORTH AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 161
TABLE 170 NORTH AMERICA: CELL THERAPY MANUFACTURING SERVICES MARKET,
BY TYPE, 2019–2026 (USD MILLION) 161
TABLE 171 NORTH AMERICA: ALLOGENEIC CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 161
TABLE 172 NORTH AMERICA: AUTOLOGOUS CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 162
TABLE 173 NORTH AMERICA: VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 162
TABLE 174 NORTH AMERICA: GENE THERAPY MANUFACTURING SERVICES MARKET,
BY VECTOR, 2019–2026 (USD MILLION) 162
TABLE 175 NORTH AMERICA: NON-VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 163
TABLE 176 NORTH AMERICA: VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 163
TABLE 177 NORTH AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY INDICATION, 2019–2026 (USD MILLION) 163
TABLE 178 NORTH AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY APPLICATION, 2019–2026 (USD MILLION) 164
TABLE 179 NORTH AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY END USER, 2019–2026 (USD MILLION) 164
10.2.1 US 164
10.2.1.1 Growing focus on cancer research in the US will drive market growth 164
TABLE 180 US: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 165
TABLE 181 US: CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 165
TABLE 182 US: ALLOGENEIC CELL THERAPY MANUFACTURING SERVICES MARKET,
BY TYPE, 2019–2026 (USD MILLION) 165
TABLE 183 US: AUTOLOGOUS CELL THERAPY MANUFACTURING SERVICES MARKET,
BY TYPE, 2019–2026 (USD MILLION) 166
TABLE 184 US: VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET,
BY TYPE, 2019–2026 (USD MILLION) 166
TABLE 185 US: GENE THERAPY MANUFACTURING SERVICES MARKET, BY VECTOR, 2019–2026 (USD MILLION) 166
TABLE 186 US: NON-VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 167
TABLE 187 US: VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET,
BY TYPE, 2019–2026 (USD MILLION) 167
TABLE 188 US: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET,
BY INDICATION, 2019–2026 (USD MILLION) 167
TABLE 189 US: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET,
BY APPLICATION, 2019–2026 (USD MILLION) 168
TABLE 190 US: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET,
BY END USER, 2019–2026 (USD MILLION) 168"
10.2.2 CANADA 168
10.2.2.1 Growth in Canada can be attributed to the rising funding for stem cell research in the country 168
TABLE 191 CANADA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET,
BY TYPE, 2019–2026 (USD MILLION) 169
TABLE 192 CANADA: CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 169
TABLE 193 CANADA: ALLOGENEIC CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 170
TABLE 194 CANADA: AUTOLOGOUS CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 170
TABLE 195 CANADA: VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 170
TABLE 196 CANADA: GENE THERAPY MANUFACTURING SERVICES MARKET, BY VECTOR, 2019–2026 (USD MILLION) 171
TABLE 197 CANADA: NON-VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 171
TABLE 198 CANADA: VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 171
TABLE 199 CANADA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET,
BY INDICATION, 2019–2026 (USD MILLION) 172
TABLE 200 CANADA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET,
BY APPLICATION, 2019–2026 (USD MILLION) 172
TABLE 201 CANADA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET,
BY END USER, 2019–2026 (USD MILLION) 172
10.3 EUROPE 173
TABLE 202 EUROPE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET,
BY COUNTRY, 2019–2026 (USD MILLION) 173
TABLE 203 EUROPE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET,
BY TYPE, 2019–2026 (USD MILLION) 173
TABLE 204 EUROPE: CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 173
TABLE 205 EUROPE: ALLOGENEIC CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 174
TABLE 206 EUROPE: AUTOLOGOUS CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 174
TABLE 207 EUROPE: VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 174
TABLE 208 EUROPE: GENE THERAPY MANUFACTURING SERVICES MARKET, BY VECTOR, 2019–2026 (USD MILLION) 175
TABLE 209 EUROPE: NON-VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 175
TABLE 210 EUROPE: VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 175
TABLE 211 EUROPE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET,
BY INDICATION, 2019–2026 (USD MILLION) 176
TABLE 212 EUROPE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET,
BY APPLICATION, 2019–2026 (USD MILLION) 176
TABLE 213 EUROPE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET,
BY END USER, 2019–2026 (USD MILLION) 176
10.3.1 GERMANY 177
10.3.1.1 Government funding for life science R&D and basic cancer research will drive market growth 177
TABLE 214 GERMANY: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET,
BY TYPE, 2019–2026 (USD MILLION) 177
TABLE 215 GERMANY: CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 177
TABLE 216 GERMANY: ALLOGENEIC CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 178
TABLE 217 GERMANY: AUTOLOGOUS CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 178
TABLE 218 GERMANY: VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 178
TABLE 219 GERMANY: GENE THERAPY MANUFACTURING SERVICES MARKET,
BY VECTOR, 2019–2026 (USD MILLION) 179
TABLE 220 GERMANY: NON-VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 179
TABLE 221 GERMANY: VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 179
TABLE 222 GERMANY: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET,
BY INDICATION, 2019–2026 (USD MILLION) 180
TABLE 223 GERMANY: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET,
BY APPLICATION, 2019–2026 (USD MILLION) 180
TABLE 224 GERMANY: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET,
BY END USER, 2019–2026 (USD MILLION) 180
10.3.2 UK 181
10.3.2.1 The rising incidence of cancer cases will lead to an increase in cancer research, which will drive market growth 181
TABLE 225 UK: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 181
TABLE 226 UK: CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 181
TABLE 227 UK: ALLOGENEIC CELL THERAPY MANUFACTURING SERVICES MARKET,
BY TYPE, 2019–2026 (USD MILLION) 182
TABLE 228 UK: AUTOLOGOUS CELL THERAPY MANUFACTURING SERVICES MARKET,
BY TYPE, 2019–2026 (USD MILLION) 182
TABLE 229 UK: VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET,
BY TYPE, 2019–2026 (USD MILLION) 182
TABLE 230 UK: GENE THERAPY MANUFACTURING SERVICES MARKET, BY VECTOR, 2019–2026 (USD MILLION) 183
TABLE 231 UK: NON-VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 183
TABLE 232 UK: VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET,
BY TYPE, 2019–2026 (USD MILLION) 183
TABLE 233 UK: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET,
BY INDICATION, 2019–2026 (USD MILLION) 184
TABLE 234 UK: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET,
BY APPLICATION, 2019–2026 (USD MILLION) 184
TABLE 235 UK: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET,
BY END USER, 2019–2026 (USD MILLION) 184
10.3.3 FRANCE 185
10.3.3.1 Growth can be attributed to rising government funding for
cancer research 185
TABLE 236 FRANCE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET,
BY TYPE, 2019–2026 (USD MILLION) 185
TABLE 237 FRANCE: CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 185
TABLE 238 FRANCE: ALLOGENEIC CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 186
TABLE 239 FRANCE: AUTOLOGOUS CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 186
TABLE 240 FRANCE: VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 186
TABLE 241 FRANCE: GENE THERAPY MANUFACTURING SERVICES MARKET, BY VECTOR, 2019–2026 (USD MILLION) 187
TABLE 242 FRANCE: NON-VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 187
TABLE 243 FRANCE: VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 187
TABLE 244 FRANCE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET,
BY INDICATION, 2019–2026 (USD MILLION) 188
TABLE 245 FRANCE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET,
BY APPLICATION, 2019–2026 (USD MILLION) 188
TABLE 246 FRANCE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET,
BY END USER, 2019–2026 (USD MILLION) 188
10.3.4 REST OF EUROPE 189
TABLE 247 ROE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 189
TABLE 248 ROE: CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 189
TABLE 249 ROE: ALLOGENEIC CELL THERAPY MANUFACTURING SERVICES MARKET,
BY TYPE, 2019–2026 (USD MILLION) 190
TABLE 250 ROE: AUTOLOGOUS CELL THERAPY MANUFACTURING SERVICES MARKET,
BY TYPE, 2019–2026 (USD MILLION) 190
TABLE 251 ROE: VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET,
BY TYPE, 2019–2026 (USD MILLION) 190
TABLE 252 ROE: GENE THERAPY MANUFACTURING SERVICES MARKET, BY VECTOR, 2019–2026 (USD MILLION) 191
TABLE 253 ROE: NON-VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 191
TABLE 254 ROE: VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET,
BY TYPE, 2019–2026 (USD MILLION) 191
TABLE 255 ROE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET,
BY INDICATION, 2019–2026 (USD MILLION) 192
TABLE 256 ROE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET,
BY APPLICATION, 2019–2026 (USD MILLION) 192
TABLE 257 ROE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET,
BY END USER, 2019–2026 (USD MILLION) 192
10.4 ASIA PACIFIC 193
FIGURE 27 ASIA PACIFIC: CELL & GENE THERAPY MANUFACTURING
SERVICES MARKET SNAPSHOT 193
TABLE 258 ASIA PACIFIC: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 194
TABLE 259 ASIA PACIFIC: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 194
TABLE 260 ASIA PACIFIC: CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 194
TABLE 261 ASIA PACIFIC: ALLOGENEIC CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 195
TABLE 262 ASIA PACIFIC: AUTOLOGOUS CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 195
TABLE 263 ASIA PACIFIC: VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 195
TABLE 264 ASIA PACIFIC: GENE THERAPY MANUFACTURING SERVICES MARKET,
BY VECTOR, 2019–2026 (USD MILLION) 196
TABLE 265 ASIA PACIFIC: NON-VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 196
TABLE 266 ASIA PACIFIC: VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 196
TABLE 267 ASIA PACIFIC: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY INDICATION, 2019–2026 (USD MILLION) 197
TABLE 268 ASIA PACIFIC: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY APPLICATION, 2019–2026 (USD MILLION) 197
TABLE 269 ASIA PACIFIC: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY END USER, 2019–2026 (USD MILLION) 197
10.4.1 CHINA 198
10.4.1.1 The growing pharmaceutical industry and rising number of CDMOs in the country will drive market growth 198
TABLE 270 CHINA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET,
BY TYPE, 2019–2026 (USD MILLION) 198
TABLE 271 CHINA: CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 199
TABLE 272 CHINA: ALLOGENEIC CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 199
TABLE 273 CHINA: AUTOLOGOUS CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 199
TABLE 274 CHINA: VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 200
TABLE 275 CHINA: GENE THERAPY MANUFACTURING SERVICES MARKET, BY VECTOR, 2019–2026 (USD MILLION) 200
TABLE 276 CHINA: NON-VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 200
TABLE 277 CHINA: VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 201
TABLE 278 CHINA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET,
BY INDICATION, 2019–2026 (USD MILLION) 201
TABLE 279 CHINA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET,
BY APPLICATION, 2019–2026 (USD MILLION) 201
TABLE 280 CHINA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET,
BY END USER, 2019–2026 (USD MILLION) 202
10.4.2 JAPAN 202
10.4.2.1 Research collaborations and growing geriatric population—
key growth drivers in Japan 202
TABLE 281 JAPAN: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET,
BY TYPE, 2019–2026 (USD MILLION) 203
TABLE 282 JAPAN: CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 203
TABLE 283 JAPAN: ALLOGENEIC CELL THERAPY MANUFACTURING SERVICES MARKET,
BY TYPE, 2019–2026 (USD MILLION) 203
TABLE 284 JAPAN: AUTOLOGOUS CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 204
TABLE 285 JAPAN: VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 204
TABLE 286 JAPAN: GENE THERAPY MANUFACTURING SERVICES MARKET, BY VECTOR, 2019–2026 (USD MILLION) 204
TABLE 287 JAPAN: NON-VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 205
TABLE 288 JAPAN: VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 205
TABLE 289 JAPAN: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET,
BY INDICATION, 2019–2026 (USD MILLION) 205
TABLE 290 JAPAN: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET,
BY APPLICATION, 2019–2026 (USD MILLION) 206
TABLE 291 JAPAN: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET,
BY END USER, 2019–2026 (USD MILLION) 206
10.4.3 REST OF ASIA PACIFIC 206
TABLE 292 ROAPAC: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET,
BY TYPE, 2019–2026 (USD MILLION) 207
TABLE 293 ROAPAC: CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 207
TABLE 294 ROAPAC: ALLOGENEIC CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 208
TABLE 295 ROAPAC: AUTOLOGOUS CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 208
TABLE 296 ROAPAC: VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 208
TABLE 297 ROAPAC: GENE THERAPY MANUFACTURING SERVICES MARKET, BY VECTOR, 2019–2026 (USD MILLION) 209
TABLE 298 ROAPAC: NON-VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 209
TABLE 299 ROAPAC: VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 209
TABLE 300 ROAPAC: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET,
BY INDICATION, 2019–2026 (USD MILLION) 210
TABLE 301 ROAPAC: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET,
BY APPLICATION, 2019–2026 (USD MILLION) 210
TABLE 302 ROAPAC: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET,
BY END USER, 2019–2026 (USD MILLION) 210
10.5 LATIN AMERICA 211
10.5.1 RISING PHARMACEUTICAL R&D EXPENDITURE IN THE REGION WILL DRIVE THE GROWTH OF THE MARKET 211
TABLE 303 LATAM: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET,
BY TYPE, 2019–2026 (USD MILLION) 211
TABLE 304 LATAM: CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 211
TABLE 305 LATAM: ALLOGENEIC CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 212
TABLE 306 LATAM: AUTOLOGOUS CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 212
TABLE 307 LATAM: VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 212
TABLE 308 LATAM: GENE THERAPY MANUFACTURING SERVICES MARKET, BY VECTOR, 2019–2026 (USD MILLION) 213
TABLE 309 LATAM: NON-VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 213
TABLE 310 LATAM: VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 213
TABLE 311 LATAM: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET,
BY INDICATION, 2019–2026 (USD MILLION) 214
TABLE 312 LATAM: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET,
BY APPLICATION, 2019–2026 (USD MILLION) 214
TABLE 313 LATAM: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET,
BY END USER, 2019–2026 (USD MILLION) 214
10.6 MIDDLE EAST & AFRICA 215
10.6.1 MARKET GROWTH DRIVEN BY CHANGING DEMOGRAPHICS AND FAVORABLE POLICIES FOR PHARMA R&D 215
TABLE 314 MEA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 215
TABLE 315 MEA: CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 216
TABLE 316 MEA: ALLOGENEIC CELL THERAPY MANUFACTURING SERVICES MARKET,
BY TYPE, 2019–2026 (USD MILLION) 216
TABLE 317 MEA: AUTOLOGOUS CELL THERAPY MANUFACTURING SERVICES MARKET,
BY TYPE, 2019–2026 (USD MILLION) 216
TABLE 318 MEA: VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET,
BY TYPE, 2019–2026 (USD MILLION) 217
TABLE 319 MEA: GENE THERAPY MANUFACTURING SERVICES MARKET, BY VECTOR, 2019–2026 (USD MILLION) 217
TABLE 320 MEA: NON-VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 217
TABLE 321 MEA: VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 218
TABLE 322 MEA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET,
BY INDICATION, 2019–2026 (USD MILLION) 218
TABLE 323 MEA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET,
BY APPLICATION, 2019–2026 (USD MILLION) 218
TABLE 324 MEA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET,
BY END USER, 2019–2026 (USD MILLION) 219
11 COMPETITIVE LANDSCAPE 220
11.1 OVERVIEW 220
11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 221
FIGURE 28 KEY PLAYER STRATEGIES IN THE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, 2018–2021 221
11.3 MARKET SHARE ANALYSIS 222
FIGURE 29 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SHARE ANALYSIS, BY KEY PLAYER, 2020 222
11.4 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS 223
FIGURE 30 REVENUE SHARE ANALYSIS OF KEY MARKET PLAYERS 223
11.5 COMPANY EVALUATION QUADRANT 224
11.5.1 STARS 224
11.5.2 EMERGING LEADERS 224
11.5.3 PERVASIVE PLAYERS 224
11.5.4 EMERGING COMPANIES 224
FIGURE 31 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET: COMPANY EVALUATION QUADRANT, 2020 225
11.6 COMPANY EVALUATION QUADRANT: START-UPS/SMES 226
11.6.1 PROGRESSIVE COMPANIES 226
11.6.2 STARTING BLOCKS 226
11.6.3 RESPONSIVE COMPANIES 226
11.6.4 DYNAMIC COMPANIES 226
FIGURE 32 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET:
COMPANY EVALUATION QUADRANT FOR START-UPS/SMES, 2020 227
11.7 SERVICE FOOTPRINT OF COMPANIES 228
TABLE 325 SERVICE PORTFOLIO ANALYSIS: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET (2020) 228
11.8 REGIONAL FOOTPRINT OF COMPANIES 229
TABLE 326 REGIONAL FOOTPRINT OF COMPANIES: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET (2020) 229
11.9 COMPETITIVE SCENARIO 230
TABLE 327 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET:
DEALS, JANUARY 2018–JUNE 2021 230
TABLE 328 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET:
OTHER DEVELOPMENTS, JANUARY 2018 –JUNE 2021 231
12 COMPANY PROFILES 232
12.1 KEY MARKET PLAYERS 232
(Business Overview, Services Offered, Recent Developments, and MnM View)*
12.1.1 THERMO FISHER SCIENTIFIC, INC. 232
TABLE 329 THERMO FISHER SCIENTIFIC, INC.: BUSINESS OVERVIEW 232
FIGURE 33 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2020) 233
12.1.2 MERCK KGAA 237
TABLE 330 MERCK KGAA: BUSINESS OVERVIEW 237
FIGURE 34 MERCK KGAA: COMPANY SNAPSHOT (2020) 238
12.1.3 CHARLES RIVER LABORATORIES 241
TABLE 331 CHARLES RIVER LABORATORIES: BUSINESS OVERVIEW 241
FIGURE 35 CHARLES RIVER LABORATORIES: COMPANY SNAPSHOT (2020) 242
12.1.4 LONZA 245
TABLE 332 LONZA: BUSINESS OVERVIEW 245
FIGURE 36 LONZA: COMPANY SNAPSHOT (2020) 246
12.1.5 CATALENT, INC. 251
TABLE 333 CATALENT, INC.: BUSINESS OVERVIEW 251
FIGURE 37 CATALENT, INC.: COMPANY SNAPSHOT (2020) 252
12.1.6 TAKARA BIO INC. 257
TABLE 334 TAKARA BIO INC.: BUSINESS OVERVIEW 257
FIGURE 38 TAKARA BIO INC.: COMPANY SNAPSHOT (2020) 258
12.1.7 OXFORD BIOMEDICA PLC 260
TABLE 335 OXFORD BIOMEDICA PLC: BUSINESS OVERVIEW 260
FIGURE 39 OXFORD BIOMEDICA PLC: COMPANY SNAPSHOT (2020) 260
12.1.8 CELL AND GENE THERAPY CATAPULT 263
TABLE 336 CELL AND GENE THERAPY CATAPULT: BUSINESS OVERVIEW 263
FIGURE 40 CELL AND GENE THERAPY CATAPULT: COMPANY SNAPSHOT (2020) 264
12.1.9 F. HOFFMANN-LA ROCHE LTD. 267
TABLE 337 F. HOFFMANN-LA ROCHE LTD.: BUSINESS OVERVIEW 267
FIGURE 41 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2020) 267
12.1.10 FUJIFILM HOLDINGS CORPORATION 269
TABLE 338 FUJIFILM HOLDINGS CORPORATION: BUSINESS OVERVIEW 269
FIGURE 42 FUJIFILM HOLDINGS CORPORATION: COMPANY SNAPSHOT (2020) 270
12.1.11 WUXI APPTEC 272
TABLE 339 WUXI APPTEC: BUSINESS OVERVIEW 272
FIGURE 43 WUXI APPTEC: COMPANY SNAPSHOT (2020) 273
12.1.12 NIKON CORPORATION 275
TABLE 340 NIKON CORPORATION: BUSINESS OVERVIEW 275
FIGURE 44 NIKON CORPORATION: COMPANY SNAPSHOT (2020) 276
12.2 OTHER PLAYERS 277
12.2.1 THE DISCOVERY LABS LLC 277
TABLE 341 THE DISCOVERY LABS LLC: BUSINESS OVERVIEW 277
12.2.2 ROSLINCT 278
TABLE 342 ROSLINCT: BUSINESS OVERVIEW 278
12.2.3 JRS PHARMA 279
TABLE 343 JRS PHARMA: BUSINESS OVERVIEW 279
12.2.4 FINVECTOR 280
TABLE 344 FINVECTOR: BUSINESS OVERVIEW 280
12.2.5 ABL, INC. 281
TABLE 345 ABL, INC.: BUSINESS OVERVIEW 281
12.2.6 RESILIENCE, INC. 283
TABLE 346 RESILIENCE, INC.: BUSINESS OVERVIEW 283
12.2.7 BIOCENTRIQ 284
TABLE 347 BIOCENTRIQ: BUSINESS OVERVIEW 284
12.2.8 PORTON BIOPHARMA LIMITED 285
TABLE 348 PORTON BIOPHARMA LIMITED: BUSINESS OVERVIEW 285
12.2.9 ANDELYN BIOSCIENCES 286
12.2.10 COMMERCIALIZING LIVING THERAPIES 286
12.2.11 VIBALOGICS 287
12.2.12 ANEMOCYTE SRL 287
12.2.13 ELEVATE BIO 288
* Business Overview, Services Offered, Recent Developments, and MnM View might not be captured in case of unlisted companies.
13 APPENDIX 289
13.1 DISCUSSION GUIDE 289
13.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 296
13.3 AVAILABLE CUSTOMIZATIONS 298
13.4 RELATED REPORTS 298
13.5 AUTHOR DETAILS 299
Sie haben eine Studie in unserem Studienshop gefunden, die das Thema Ihrer Recherche trifft, aber noch nicht vollkommen passgenau ist?
Schreiben Sie uns in diesem Falle bitte eine E-Mail an service@marktforschung.de in der Sie uns beschreiben, wie die Studie genau auf Sie angepasst werden kann. Wir werden uns dann mit den Herausgebern in Verbindung setzen und versuchen, die bestmöglichen Daten für Sie erstellen zu lassen.
Gerne können Sie uns auch telefonisch unter folgender Nummer erreichen: +49 (0)2233 46078 60
CONSULTING.de
PERSONALintern.de
